On February 22, the Third People's Hospital of Shenzhen, the Shenzhen National Clinical Research Center for Infectious Diseases and Hanyu Pharmaceutical held a strategic cooperation signing and listing ceremony in Shenzhen to jointly build a "collaborative innovation center and practice base for translational medicine of infectious diseases" and build a clinical research innovation system for infectious diseases, so as to accelerate the clinical research and application of new drugs, improve the clinical diagnosis and treatment level of infectious diseases in the mainland, and drive the development of medical and health undertakings.
According to the agreement, the "Collaborative Innovation Center and Practice Base for Translational Medicine of Infectious Diseases" jointly established by the three parties will work together to break the inherent barriers between basic medicine and drug research and development, clinical and public health in the field of infectious diseases, establish direct connections, and quickly transform the knowledge and achievements obtained from basic research from the laboratory to the hospital bed into new methods of clinical and public health prevention and treatment.
At the same time, the three parties will carry out comprehensive strategic cooperation in the cooperative development of innovative projects, the declaration of scientific research projects, project transformation, industry-university-research academic exchanges, and the exchange and training of composite talents, so as to form a good situation in which medical units and enterprises promote each other and develop together, and strive to achieve the trend of "cooperation between institutes and enterprises, strong and strong cooperation, win-win results between industry and education, and service to society".
Shenzhen Third People's Hospital is a modern tertiary first-class research hospital with "strong specialty, large synthesis", which has been built into one of the largest, most advanced and most complete infectious disease diagnosis and treatment and research centers in the Pearl River Delta region such as Shenzhen, Hong Kong and Macao, mainly undertaking the prevention and control tasks of infectious diseases and major epidemics in Shenzhen and surrounding areas and carrying out comprehensive medical services.
Liu Lei, Secretary of the Party Committee of the Third People's Hospital of Shenzhen and Director of the Shenzhen National Clinical Research Center for Infectious Diseases, said that the Third People's Hospital of Shenzhen and the Shenzhen National Clinical Research Center for Infectious Diseases have rich clinical medical research resources, research and development, and medical talent resources, and have broad cooperation space and prospects with Hanyu Pharmaceutical in clinical research and product promotion.
Liu Lei said that he hopes that the three parties will carry out exchanges in medical resource sharing, technology research and development innovation, academic research and other aspects, strengthen clinical and basic research on infection through the integration of innovative research and development resources, promote the comprehensive landing of cooperation projects, rely on scientific research strength to do a good job in the prevention and control of infectious diseases, and promote the rapid development of infectious diseases in Shenzhen.
Hanyu Pharmaceutical is a "national high-tech enterprise" specializing in the research and development, production and sales of peptide drugs, with a sound peptide industry chain, a first-class professional R & D team, and a technology research and development platform for many countries, provinces and cities. At the same time, based on its own peptide drug research and development capabilities and technological innovation capabilities, the company has worked closely with top domestic scientific research institutes to strengthen technical research and make every effort to promote the development of new nasal spray drugs, and has made phased progress.
Zeng Shaogui, chairman of Hanyu Pharmaceutical, said that the company will actively embrace the wave of pharmaceutical innovation, give full play to the strength of peptide drug technology research and development, innovation, etc., with the help of the partners' medical, scientific research and talent strength, actively carry out the research and development, technical research and transformation of innovative drugs such as new crown polypeptide drugs, so that more and better innovative drugs can be successfully landed, protect people's lives and health, and provide strong support for the development of medical undertakings in Shenzhen and the whole country.
